In conclusion, there is evidence, albeit of limited quality, that ALK positive NSCLC patients with BMs derive significant clinical benefit from ALK inhibitors with or without previous (whole) brain radiotherapy, and the efficacy is similar to that observed for extracranial systemic disease. The gene discussed is ALK; the disease is non-small cell lung carcinoma.